 Connection
Andrew Haynes to Anti-Bacterial Agents
This is a "connection" page, showing publications Andrew Haynes has written about Anti-Bacterial Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.061 |
|
|
|
-
Haynes AS, Wei Z, Scheetz MH, Gonzalez D, Messacar K, Tang Girdwood S, Peloquin CA, Fish DN, Anderson P. Oral Cephalexin Population Pharmacokinetics and Target Attainment Analysis in Infants 7-60 Days Old. J Pediatric Infect Dis Soc. 2025 Oct 02; 14(10).
Score: 0.425
-
Haynes AS, Wei Z, Anderson P, Scheetz MH, Parker SK, Fish DN. Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections. Antimicrob Agents Chemother. 2024 05 02; 68(5):e0018224.
Score: 0.383
-
Haynes AS, Maples H, Parker S. Time for a Change: Considering Vancomycin Alternatives for Pediatric Methicillin-Resistant Staphylococcus aureus Bacteremia. J Pediatric Infect Dis Soc. 2023 May 31; 12(5):308-318.
Score: 0.090
-
Haynes AS, Prinzi A, Silveira LJ, Parker SK, Lampe JN, Kavanaugh JS, Horswill AR, Fish D. Cefadroxil Comparable to Cephalexin: Minimum Inhibitory Concentrations among Methicillin-Susceptible Staphylococcus aureus Isolates from Pediatric Musculoskeletal Infections. Microbiol Spectr. 2022 08 31; 10(4):e0103922.
Score: 0.085
-
Haynes AS, MacBrayne CE, Parker SK. Impact of Antimicrobial Stewardship Bundle on Inpatient Use of Highly Bioavailable Antibacterials. Hosp Pediatr. 2021 05; 11(5):509-514.
Score: 0.078
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|